دورية أكاديمية
أعرض في EDS

Structural Basis of Colchicine-Site targeting Acylhydrazones active against Multidrug-Resistant Acute Lymphoblastic Leukemia.

التفاصيل البيبلوغرافية
العنوان: Structural Basis of Colchicine-Site targeting Acylhydrazones active against Multidrug-Resistant Acute Lymphoblastic Leukemia.
المؤلفون: Cury NM; Laboratório de Biologia Molecular, Centro Infantil Boldrini, Rua Dr. Gabriel Porto 1270, Campinas 13083-210, Brazil; Graduate Program in Genetics and Molecular Biology, State University of Campinas, Campinas 13083-210, Brazil., Mühlethaler T; Laboratory of Biomolecular Research, Division of Biology and Chemistry, Paul Scherrer Institut, 5232 Villigen PSI, Switzerland., Laranjeira ABA; Laboratório de Biologia Molecular, Centro Infantil Boldrini, Rua Dr. Gabriel Porto 1270, Campinas 13083-210, Brazil., Canevarolo RR; Laboratório de Biologia Molecular, Centro Infantil Boldrini, Rua Dr. Gabriel Porto 1270, Campinas 13083-210, Brazil., Zenatti PP; Laboratório de Biologia Molecular, Centro Infantil Boldrini, Rua Dr. Gabriel Porto 1270, Campinas 13083-210, Brazil., Lucena-Agell D; Centro de Investigaciones Biológicas, CSIC, 28006 Madrid, Spain., Barasoain I; Centro de Investigaciones Biológicas, CSIC, 28006 Madrid, Spain., Song C; Pennsylvania State University College of Medicine, Department of Pediatrics, Hershey, PA 17033, USA., Sun D; Pennsylvania State University College of Medicine, Department of Pediatrics, Hershey, PA 17033, USA., Dovat S; Pennsylvania State University College of Medicine, Department of Pediatrics, Hershey, PA 17033, USA., Yunes RA; Department of Chemistry, Federal University of Santa Catarina, Florianópolis 88040-900, Brazil., Prota AE; Laboratory of Biomolecular Research, Division of Biology and Chemistry, Paul Scherrer Institut, 5232 Villigen PSI, Switzerland., Steinmetz MO; Laboratory of Biomolecular Research, Division of Biology and Chemistry, Paul Scherrer Institut, 5232 Villigen PSI, Switzerland; University of Basel, Biozentrum, 4056 Basel, Switzerland., Díaz JF; Centro de Investigaciones Biológicas, CSIC, 28006 Madrid, Spain., Yunes JA; Laboratório de Biologia Molecular, Centro Infantil Boldrini, Rua Dr. Gabriel Porto 1270, Campinas 13083-210, Brazil; Genetics Department, Faculty of Medical Sciences, State University of Campinas, Campinas 13083-887, Brazil. Electronic address: andres@boldrini.org.br.
المصدر: IScience [iScience] 2019 Nov 22; Vol. 21, pp. 95-109. Date of Electronic Publication: 2019 Oct 02.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101724038 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2589-0042 (Electronic) Linking ISSN: 25890042 NLM ISO Abbreviation: iScience Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Cambridge, MA] : Cell Press, [2018]-
مستخلص: Tubulin is one of the best validated anti-cancer targets, but most anti-tubulin agents have unfavorable therapeutic indexes. Here, we characterized the tubulin-binding activity, the mechanism of action, and the in vivo anti-leukemia efficacy of three 3,4,5-trimethoxy-N-acylhydrazones. We show that all compounds target the colchicine-binding site of tubulin and that none is a substrate of ABC transporters. The crystal structure of the tubulin-bound N-(1'-naphthyl)-3,4,5-trimethoxybenzohydrazide (12) revealed steric hindrance on the T7 loop movement of β-tubulin, thereby rendering tubulin assembly incompetent. Using dose escalation and short-term repeated dose studies, we further report that this compound class is well tolerated to >100 mg/kg in mice. We finally observed that intraperitoneally administered compound 12 significantly prolonged the overall survival of mice transplanted with both sensitive and multidrug-resistant acute lymphoblastic leukemia (ALL) cells. Taken together, this work describes promising colchicine-site-targeting tubulin inhibitors featuring favorable therapeutic effects against ALL and multidrug-resistant cells.
(Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.)
References: Br J Haematol. 2005 Jul;130(1):67-75. (PMID: 15982346)
Curr Opin Pharmacol. 2001 Aug;1(4):370-7. (PMID: 11710735)
J Cell Sci. 1992 Jul;102 ( Pt 3):401-16. (PMID: 1506423)
FEBS J. 2016 Jan;283(1):102-11. (PMID: 26462166)
Pediatr Blood Cancer. 2016 Jun;63(6):997-1005. (PMID: 26891067)
Eur J Med Chem. 2015;96:504-18. (PMID: 25951294)
J Med Chem. 2016 Nov 23;59(22):10329-10334. (PMID: 27805821)
Sci Rep. 2018 Mar 9;8(1):4242. (PMID: 29523799)
J Comput Aided Mol Des. 2014 Jul;28(7):751-63. (PMID: 24916062)
J Clin Oncol. 1996 Feb;14(2):389-98. (PMID: 8636748)
PLoS One. 2012;7(3):e33894. (PMID: 22479469)
Br J Cancer. 2003 Mar 10;88(5):775-81. (PMID: 12618889)
PLoS One. 2016 May 26;11(5):e0156048. (PMID: 27227832)
Int J Nanomedicine. 2013;8:4361-9. (PMID: 24232122)
Haematologica. 2016 Jan;101(1):68-76. (PMID: 26494838)
Leuk Lymphoma. 2002 Feb;43(2):309-14. (PMID: 11999562)
J Cell Biol. 2013 Feb 4;200(3):259-70. (PMID: 23358242)
J Nat Prod. 2016 Aug 26;79(8):2113-21. (PMID: 27518758)
Biochem Pharmacol. 1976 Jun 15;25(12):1383-7. (PMID: 938560)
J Mol Biol. 2014 Apr 17;426(8):1848-60. (PMID: 24530796)
N Engl J Med. 2004 Aug 5;351(6):533-42. (PMID: 15295046)
Bioorg Med Chem. 2014 Sep 15;22(18):5050-9. (PMID: 24650703)
Cancer Res. 1995 Mar 1;55(5):1086-91. (PMID: 7866993)
Int J Cancer. 1992 Jan 21;50(2):305-10. (PMID: 1370437)
Sao Paulo Med J. 2004 Jul 1;122(4):166-71. (PMID: 15543372)
Protein Sci. 2015 Jul;24(7):1164-72. (PMID: 25970265)
Nature. 2004 Mar 11;428(6979):198-202. (PMID: 15014504)
Int J Clin Pharmacol Ther. 2000 Mar;38(3):94-110. (PMID: 10739113)
Science. 2013 Feb 1;339(6119):587-90. (PMID: 23287720)
Cancer. 2013 Jan 1;119(1):90-8. (PMID: 22744771)
Expert Opin Ther Pat. 2014 Jan;24(1):69-88. (PMID: 24313741)
Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8661-8. (PMID: 16361551)
Front Pharmacol. 2017 Jan 10;7:535. (PMID: 28119610)
معلومات مُعتمدة: R01 CA209829 United States CA NCI NIH HHS; R01 CA213912 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: Biological Sciences; Cancer; Drugs; Molecular Biology; Structural Biology
تواريخ الأحداث: Date Created: 20191027 Latest Revision: 20200928
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC6820235
DOI: 10.1016/j.isci.2019.10.003
PMID: 31655259
قاعدة البيانات: MEDLINE
الوصف
تدمد:2589-0042
DOI:10.1016/j.isci.2019.10.003